ArticleScientific reports2026
Computational identification of multi-target natural compounds from Sesbania grandiflora as potential therapeutic agents against Klebsiella pneumoniae.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- EBV-informed multi-omics target prioritization and structure-based drug repurposing reveal potential therapeutic strategies for multiple sclerosis.Functional & integrative genomics · 2026Article
- Structure-Based Identification of Allosteric Glucocerebrosidase Stabilizers fromPlants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Klebsiella pneumoniae (K. pneumoniae) is a Gram-negative bacterium that causes severe community- and hospital-acquired infections. Its rising multidrug resistance complicates therapy, highlighting the need for novel drugs with broad-spectrum, multi-target potential. Leveraging the traditional use and therapeutic evidence of Sesbania grandiflora, this study performed structure-based computational screening of its phytochemicals against K. pneumoniae targets. Initially, 93 proteins with high annotation scores and resolved X-ray structures were identified. Six key therapeutic targets, including LpxH, fabG, KPC-2, GlmU, chbG, and ompA, were prioritized for their pathogenic role. Molecular docking revealed that 59 of 73 compounds interacted with all six targets with high affinity, while the remaining 14 compounds interacted with five targets. Network pharmacology indicated KPC-2, fabG, and ompA had the highest connectivity (73 compounds), followed by chbG and LpxH (72), and GlmU (61). ‘3′,6-di-O-feruloylsucrose’ had the strongest affinity for ompA, LpxH, and GlmU, while ‘Acarbose hydrate’ ranked top for chbG, fabG, and KPC-2. Out of 47 drug-like compounds, 9 passed ADMET filters. Sonchuionoside A was selected for molecular dynamics simulations, demonstrating stable binding to all targets. This suggests S. grandiflora phytoconstituents as multi-target regulators against K. pneumoniae and highlights Sonchuionoside A as a promising lead for further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.